Showing 521 - 540 results of 1,061 for search '"lymphoma"', query time: 0.06s Refine Results
  1. 521

    Isolated Central Nervous System Involvement after Brentuximab Vedotin Treatment for HIV-Positive ALK-Negative Anaplastic Large Cell Lymphoma by Takuya Suyama, Kumiko Matsui, Kosuke Makihara, Masatoshi Tsuru

    Published 2024-01-01
    “…Human immunodeficiency virus (HIV)-associated lymphoma poses a high mortality risk despite antiretroviral therapy (ART). …”
    Get full text
    Article
  2. 522

    A Unique Case of Malignant Pleuropericardial Effusion: HHV-8-Unrelated PEL-Like Lymphoma—A Case Report and Review of the Literature by Farhan Mohammad, Muhammad Neaman Siddique, Faraz Siddiqui, M. Popalzai, Masoud Asgari, Marcel Odaimi

    Published 2014-01-01
    “…Primary effusion lymphoma (PEL) or body cavity lymphoma is a rare type of extra nodal lymphoma of B-cell origin that presents as lymphomatous effusion(s) without any nodal enlargement or tumor masses. …”
    Get full text
    Article
  3. 523

    Assessing Metabolic Changes in Response to mTOR Inhibition in a Mantle Cell Lymphoma Xenograft Model Using AcidoCEST MRI by Paul J. Akhenblit PhD, Neale T. Hanke PhD, Alexander Gill BS, Daniel O. Persky MD, Christine M. Howison MS, Mark D. Pagel PhD, Amanda F. Baker PharmD, PhD

    Published 2016-04-01
    “…To perform this study, we used the Granta 519 human mantle cell lymphoma cell line, which is an aggressive B-cell malignancy that demonstrates activation of the phosphatidylinositol-3-kinase/Akt/mammalian target of rapamycin (mTOR) pathway. …”
    Get full text
    Article
  4. 524
  5. 525
  6. 526
  7. 527

    Daratumumab, Lenalidomide, and Dexamethasone (DRD), an Active Regimen in the Treatment of Immunosuppression-Associated Plasmablastic Lymphoma (PBL) in the Setting of Gorham’s Lymphangiomatosis: Review of the Literature by Matthew Lee, Beth A. Martin, Haifaa Abdulhaq

    Published 2022-01-01
    “…Characterized by an aggressive course with a poor overall survival due to treatment refractoriness, plasmablastic lymphoma (PBL) is a rare variant of diffuse large cell B cell lymphoma. …”
    Get full text
    Article
  8. 528
  9. 529
  10. 530
  11. 531

    Cavitating Mesenteric Lymph Node Syndrome in Association with Coeliac Disease and Enteropathy Associated T-Cell Lymphoma: A Case Report and Review of the Literature by Olivia M. B. McBride, Richard J. E. Skipworth, Derek Leitch, Satheesh Yalamarthi

    Published 2010-01-01
    “…This is associated with serious complications such as enteropathy-associated T-cell lymphoma (EATL). We present the case of a 71-year-old female investigated for weight loss and a palpable intraabdominal mass. …”
    Get full text
    Article
  12. 532

    Gingival Anaplastic Large-Cell Lymphoma Mimicking Hyperplastic Benignancy as the First Clinical Manifestation of AIDS: A Case Report and Review of the Literature by Rafaela Elvira Rozza-de-Menezes, Stefânia Jeronimo Ferreira, Diogo Lenzi Capella, Stephan Schwartz, Ana Helena Willrich, Lúcia de Noronha, Aline Cristina Batista Rodrigues Johann, Paulo Henrique Couto Souza

    Published 2013-01-01
    “…Oral anaplastic large-cell lymphoma (ALCL) is a rare disorder. Only 5 cases involving the gingiva have been reported, and to our knowledge, this is the first case reported of the ALCL, which mimicked a hyperplastic benignancy as the first clinical manifestation of AIDS.…”
    Get full text
    Article
  13. 533
  14. 534

    Integrating multi‐omics features enables non‐invasive early diagnosis and treatment response prediction of diffuse large B‐cell lymphoma by Weilong Zhang, Bangquan Ye, Yang Song, Ping Yang, Wenzhe Si, Hairong Jing, Fan Yang, Dan Yuan, Zhihong Wu, Jiahao Lyu, Kang Peng, Xu Zhang, Lingli Wang, Yan Li, Yan Liu, Chaoling Wu, Xiaoyu Hao, Yuqi Zhang, Wenxin Qi, Jing Wang, Fei Dong, Zijian Zhao, Hongmei Jing, Yanzhao Li

    Published 2025-01-01
    “…The COMOS was tested on 214 plasma samples of diffuse large B‐cell lymphoma (DLBCL) and matched healthy controls. Results For early diagnosis, COMOS improved the area under the curve (AUC) value to .993 compared with the individual omics model, with a sensitivity of 95% at 98% specificity. …”
    Get full text
    Article
  15. 535

    Sp17 Protein Expression and Major Histocompatibility Class I and II Epitope Presentation in Diffuse Large B Cell Lymphoma Patients by Kamel Ait-Tahar, Amanda P. Anderson, Martin Barnardo, Graham P. Collins, Chris S. R. Hatton, Alison H. Banham, Karen Pulford

    Published 2017-01-01
    “…Improved therapies are urgently needed for patients with diffuse large B cell lymphoma (DLBCL). Success using immune checkpoint inhibitors and chimeric antigen receptor T cell technology has fuelled demand for validated cancer epitopes. …”
    Get full text
    Article
  16. 536

    Cost-effectiveness Analysis of Lorlatinib in Patients Previously Treated with Anaplastic Lymphoma Kinase Inhibitors for Non-small Cell Lung Cancer in Greece by George Gourzoulidis, Oresteia Zisimopoulou, Nadia Boubouchairopoulou, Christina Michailidi, Chrissy Lowry, Charalampos Tzanetakos, Georgia Kourlaba

    Published 2022-02-01
    “…Lorlatinib is a potent third-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of patients with advanced, ALK-positive NSCLC previously treated with at least one second-generation ALK tyrosine kinase inhibitor. …”
    Get full text
    Article
  17. 537
  18. 538
  19. 539
  20. 540